Publications in 2016

A small molecule inhibitor of mutant IDH2 rescues cardiomyopathy in a D-2-hydroxyglutaric aciduria type II mouse module

Wang F, Travins J, Lin Z, Si Y, Chen Y, Powe J, Murray S, Zhu D, Artin E, Gross S, Santiago S, Steadman M, Kernytsky A, Straley K, Lu C, Pop A, Struys EA, Jansen EE, Salomons GS, David MD, Quivoron C, Penard-Lacronique V, Regan KS, Liu W, Dang L, Yang H, Silverman L, Agresta S, Dorsch M, Biller S, Yen K, Cang Y, Su SM, Jin S.

J Inherit Metab Dis. 2016 Jul; 39(6): 807–820

PMID: 27469509

The promises of quantitative systems pharmacology modelling for drug development

Knight-Schrijver VR, Chelliah V, Cucurull-Sanchez L, Le Novère N.

Comput Struct Biotechnol J. 2016 Sep;14:363-370

PMID: 27761201


Recent growth in annual new therapeutic entity (NTE) approvals by the U.S. Food and Drug Administration (FDA) suggests a positive trend in current research and development (R&D) output.

The role of chronic toxicology studies in revealing new toxicities

Galijatovic-Idrizbegovic A, Miller JE, Cornell WD, Butler JA, Wollenberg GK, Sistare FD, DeGeorge JJ.

Regul Toxicol Pharmacol. 2016 Oct; pii: S0273-2300(16)30299-9

PMID: 27769827


Chronic (>3 months) preclinical toxicology studies are conducted to support the safe conduct of clinical trials exceeding 3 months in duration.

Reflection of successful anticancer drug development processes in the literature

Heinemann F, Huber T, Meisel C, Bundschus M, Leser U.

Drug Discov Today. 2016 Nov 16

PMID: 27443674

Use of data mining at the Food and Drug Administration

Duggirala HJ, Tonning JM, Smith E, Bright RA, Baker JD, Ball R, Bell C, Bright-Ponte SJ, Botsis T, Bouri K, Boyer M, Burkhart K, Condrey GS, Chen JJ, Chirtel S, Filice RW, Francis H, Jiang H, Levine J, Martin D, Oladipo T, O'Neill R, Palmer LA, Paredes A, Rochester G, Sholtes D, Szarfman A, Wong HL, Xu Z, Kass-Hout T.

J Am Med Inform Assoc. 2016 Mar;23(2):428-34